- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00643526
A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector
9. april 2015 opdateret af: Centocor, Inc.
An Open-Label, Randomized, Validation Study to Establish That the Design, Functionality, and Ergonomic Features of the Autoinjector Conform to Defined User Needs and Intended Use for Self-Administration by Subjects With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Psoriasis
The main purpose of this study is to evaluate how well the autoinjector works in a group of people who are likely to use the autoinjector for injecting their medicine in the future.
However, no active medicine is given by the autoinjector.
Studieoversigt
Status
Afsluttet
Intervention / Behandling
Detaljeret beskrivelse
This device (called an autoinjector) automatically injects medicine under the skin with a sterile needle, and is similar to other types of autoinjectors currently being used for this purpose.
This trial has been designed to make sure that people, who are likely to use this device, are able to self-inject and understand the training material.
A total of 68 subjects took part in the study.
About half (30 patients) will have either Rheumatoid Arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and the other half will have psoriasis (a type of skin disease), since this device will be used by patients with one of these diseases to inject their medication.
The study is designed to have each patient complete 2 self-injections with the autoinjector in 2 different sites-one in the front of the thigh and one in the abdomen 2 inches away from the navel.
The order of the first injection location is decided by randomization.
The patient will have an equal chance of having the thigh or the abdomen as the first injection.
The study staff will assess the subject's safety prior to the patient leaving the clinic.
Two prefilled, 1mL placebo autoinjectors for subcutaneous injection
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
68
Fase
- Tidlig fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Florida
-
Miami, Florida, Forenede Stater
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Forenede Stater
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Have the capacity to understand and sign an informed consent form
- Have one of the following diagnoses: rheumatoid arthritis/psoriatic arthritis/ankylosing spondylitis, or psoriasis
- Be willing and able to self-inject
Exclusion Criteria:
- Have a recent history of (within 6 months prior to study entry) or current diagnosis of a major bleeding or coagulation disorder
- Have a prior history of a inability to use an autoinjector
- Have an allergy to latex or any component of the autoinjector
- Female participants who are pregnant
- Are unwilling to complete the study assessments
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Injection Site: First Thigh Then Abdomen
Participants will self inject subcutaneously placebo using auto injector at thigh followed by self injection of placebo subcutaneously at abdomen on Day 1.
|
Participants will self-inject placebo subcutaneously at thigh and abdomen.
|
Eksperimentel: Injection Site: First Abdomen then Thigh
Participants will self inject subcutaneously placebo using auto injector at abdomen followed by self injection of placebo subcutaneously at thigh on Day 1.
|
Participants will self-inject placebo subcutaneously at thigh and abdomen.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
To establish that the autoinjector, as designed, meets defined user needs and intended use for self administration by patients with RA, PsA, AS, and psoriasis
Tidsramme: Day 1
|
Day 1
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
•To establish that the specific training, including the instructional video and the Instructions for Use, are appropriate, easy to understand, and able to be followed and implemented by patients with RA, PsA, AS, and psoriasis.
Tidsramme: Day 1
|
Day 1
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2007
Primær færdiggørelse (Faktiske)
1. januar 2008
Studieafslutning (Faktiske)
1. januar 2008
Datoer for studieregistrering
Først indsendt
22. februar 2008
Først indsendt, der opfyldte QC-kriterier
24. marts 2008
Først opslået (Skøn)
26. marts 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
10. april 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
9. april 2015
Sidst verificeret
1. april 2015
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hudsygdomme
- Infektioner
- Sygdomme i immunsystemet
- Autoimmune sygdomme
- Ledsygdomme
- Muskuloskeletale sygdomme
- Reumatiske sygdomme
- Bindevævssygdomme
- Hudsygdomme, Papulosquamous
- Rygmarvssygdomme
- Knoglesygdomme
- Spondylarthropatier
- Knoglesygdomme, smitsom
- Ankylose
- Gigt
- Gigt, reumatoid
- Psoriasis
- Gigt, psoriasis
- Spondylitis
- Spondylarthritis
- Spondylitis, ankyloserende
Andre undersøgelses-id-numre
- CR014914
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Rheumatoid arthritis
-
Janssen Research & Development, LLCTrukket tilbageAktiv reumatoid arthritis; Rheumatoid arthritis
-
Hamad Medical CorporationUkendtRHEUMATOID ARTHRITISQatar
-
Healthcare Homoeo Charitable SocietyUkendtRheumatoid arthritis.Indien
-
Federal University of São PauloAfsluttetRheumatoid arthritis.Brasilien
-
Richard Burt, MDAfsluttet
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloUkendt- Rheumatoid arthritisBrasilien
-
Biomet Orthopedics, LLCNew Lexington ClinicAfsluttetSlidgigt | Rheumatoid arthritis | Knæ arthritis | Degenerativ arthritisForenede Stater
-
Biomet Orthopedics, LLCNew Lexington ClinicAfsluttetSlidgigt | Rheumatoid arthritis | Knæ arthritis | Degenerativ arthritisForenede Stater
-
University of SalfordAfsluttetRheumatoid arthritis | Håndslidgigt | Inflammatorisk arthritisDet Forenede Kongerige
-
Link America, Inc.AfsluttetSlidgigt | Rheumatoid arthritis | Post-traumatisk arthritisForenede Stater
Kliniske forsøg med Pre-filled Auto-injector Containing Placebo
-
PfizerAfsluttetEpilepsi | Epilepsi, generaliseret | Anfald | Epilepsi, Delvis | Epilepsi, kompleks delvisForenede Stater